What is Biogen's royalty and other revenue — total revenue?

Biogen (BIIB) reported royalty and other revenue — total revenue of $9.70M in Q1 2026.

How has Biogen's royalty and other revenue — total revenue changed year-over-year?

Biogen's royalty and other revenue — total revenue decreased by 11.8% year-over-year, from $11.00M to $9.70M.

What is the long-term trend for Biogen's royalty and other revenue — total revenue?

Over 2 years (2021 to 2025), Biogen's royalty and other revenue — total revenue has grown at a 38.5% compound annual growth rate (CAGR), from $27.90M to $53.50M.

What does royalty and other revenue — total revenue mean?

Total income earned from licensing intellectual property and royalty agreements with third-party partners.

Products & Services · Total Revenue

Royalty and other revenue — Total Revenue

Biogen Royalty and other revenue — Total Revenue decreased by 26.5% to $9.70M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 11.8%, from $11.00M to $9.70M. Over 2 years (FY 2021 to FY 2025), Royalty and other revenue — Total Revenue shows an upward trend with a 38.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.

Analysis

StatementSegment

CategoryGrowth

SignalHigher is better

VolatilityModerate

First reportedQ1 2016

Last reportedQ1 2026

Rolls up toTotal Revenue

How to read this metric

An increase indicates successful monetization of intellectual property or higher sales performance by partners, while a decrease may signal expiring patents or declining market share for licensed products.

Detailed definition

This metric represents the total revenue generated from royalty streams, licensing agreements, and ancillary service arr...

Peer comparison

Peer pharmaceutical companies typically report this under 'Royalty Revenue' or 'Licensing Income,' often benchmarked against the total revenue mix to assess reliance on non-core commercialization activities.

Metric ID: biib_segment_royalty_and_other_revenue_total_revenue

Historical Data

18 periods

	Q2 '21	Q3 '21	Q4 '21	Q1 '22	Q2 '22	Q3 '22	Q4 '22	Q1 '23	Q2 '23	Q3 '23	Q1 '24	Q2 '24	Q3 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
Value	$6.40M	$7.70M	$7.60M	$10.60M	$10.30M	$8.80M	$37.70M	$12.20M	$14.40M	$51.30M	$32.40M	$20.80M	$28.30M	$11.00M	$19.60M	$9.70M	$13.20M	$9.70M
QoQ Change	—	+20.3%	-1.3%	+39.5%	-2.8%	-14.6%	+328.4%	-67.6%	+18.0%	+256.3%	-36.8%	-35.8%	+36.1%	-61.1%	+78.2%	-50.5%	+36.1%	-26.5%
YoY Change	—	—	—	—	+60.9%	+14.3%	+396.1%	+15.1%	+39.8%	+483.0%	+165.6%	+44.4%	-44.8%	-66.0%	-5.8%	-65.7%	—	-11.8%

Range$6.40M – $51.30M

CAGR+10.3%

Avg YoY Growth+78.8%

Median YoY Growth+15.1%

Similar Metrics at Other Companies

Bristol-Myers SquibbBMY View metric

Natera, Inc.NTRA View metric

QualcommQCOM View metric

Tapestry, Inc.TPR View metric

Frequently Asked Questions

What is Biogen's royalty and other revenue — total revenue?: Biogen (BIIB) reported royalty and other revenue — total revenue of $9.70M in Q1 2026.
How has Biogen's royalty and other revenue — total revenue changed year-over-year?: Biogen's royalty and other revenue — total revenue decreased by 11.8% year-over-year, from $11.00M to $9.70M.
What is the long-term trend for Biogen's royalty and other revenue — total revenue?: Over 2 years (2021 to 2025), Biogen's royalty and other revenue — total revenue has grown at a 38.5% compound annual growth rate (CAGR), from $27.90M to $53.50M.
What does royalty and other revenue — total revenue mean?: Total income earned from licensing intellectual property and royalty agreements with third-party partners.